Juno therapeutics stock price
Jan 22, 2018 · Celgene Buys Juno Therapeutics: A Risky $9B Bet Juno’s share price spiked more than 26 percent today to just under $86 a share. Celgene’s stock price, however, barely moved, rising a tepid Juno Therapeutics Company Profile: Acquisition & Investors ... Juno Therapeutics Inc is a US-based biopharmaceutical company. It is focused on developing cellular immunotherapies for the treatment of cancer. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.